Esketamine injection just after childbirth reduces depression in new mothers: BMJ

Esketamine is made from a drug called ketamine. It’s used as an anaesthetic and to treat depression, yet the effect for mothers with perinatal depression is unclear.

Researchers have found in a new clinical trial that  single low dose injection of esketamine given immediately after childbirth may  reduce major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression). The findings of the clinical trial has been published by The BMJ today.

The results suggest that low dose esketamine should be considered in new mothers with prenatal depressive symptoms.

Depression is common during pregnancy and shortly after giving birth and can have several adverse effects on new mothers and their infants.

To examine this further, researchers based in China and the USA wanted to find out if a single low dose injection of esketamine given just after childbirth might reduce subsequent depression in mothers with pre-existing prenatal depression.

Their findings are based on 361 mothers (average age 32 years) enrolled from five Chinese hospitals from June 2020 to August 2022 with no medical history of depression and no diagnosis of depression in pregnancy, but who had scores on a scale consistent with mild prenatal depression and were preparing for childbirth.

None of the participants had severe pregnancy complications, or any condition that meant they couldn’t be given esketamine.

Information on factors including age, weight (BMI), education level, family income and existing health conditions was recorded at the start of the trial and participants were randomly assigned to either esketamine or placebo intravenously infused over 40 minutes after childbirth.

Participants were interviewed 18 to 30 hours after giving birth and again at 7 and 42 days.

Major depressive episode was diagnosed with the Mini-International Neuropsychiatric Interview at 42 days. Depression was also assessed using the Edinburgh depression score at 7 and 42 days, and the Hamilton Depression Rating Scale score at 42 days. No participant took antidepressants or received psychotherapy during the follow-up period.

At 42 days after giving birth, 12 of 180 (6.7%) of mothers given esketamine experienced a major depressive episode compared with 46 of 181 (25.4%) of those given placebo (a relative risk reduction of about three-quarters).

As expected, mothers given esketamine had lower Edinburgh depression scores at 7 and 42 days, and a lower Hamilton depression score at 42 days.

Based on these figures, the researchers estimate that, for every five mothers given esketamine, one major depressive episode would be prevented.

More neuropsychiatric adverse events such as dizziness and diplopia (double vision) occurred with esketamine (45% v 22%). However, symptoms lasted less than a day and none needed drug treatment.

The researchers acknowledge that excluding mothers with pre-pregnancy mood disorders may have affected the validity of their results, and the short follow-up period may have led to under-reporting of neuropsychiatric symptoms and other adverse events.

What’s more, most participants had only mild prenatal depressive symptoms, so it’s unclear whether esketamine is equally effective in those with more severe depressive symptoms.

Nevertheless, they conclude that for mothers with prenatal depressive symptoms, a single low dose of esketamine given shortly after childbirth decreases major depressive episodes at 42 days postpartum by about three quarters.

These results are generally consistent with previous work investigating the effects of low dose ketamine or esketamine on postpartum depression, mainly in mothers after caesarean delivery, and, importantly, the researchers say their trial “extends existing understanding by targeting women with pre-existing prenatal depression, who were therefore at high risk of postnatal depression.”

As such, they conclude that low dose esketamine should be considered in mothers with symptoms of prenatal depression.

References: Shuo Wang, attending physician1, Chun-Mei Deng, attending physician1, Yuan Zeng, associate professor1, Xin-Zhong Chen, consultant physician2, Ai-Yuan Li, consultant physician3, Shan-Wu Feng, professor4, Li-Li Xu, consultant physician2, Liang Chen, consultant physician3, Hong-Mei Yuan, consultant physician4, Han Hu, attending physician2, Tian Yang, attending physician3, Tao Han, attending physician3, Hui-Ying Zhang, attending physician4, Ming Jiang, attending physician4, Xin-Yu Sun, professor5, Hui-Ning Guo, attending psychiatrist5, Daniel I Sessler, professor67, Dong-Xin Wang, professor17 BMJ 2024; 385 doi: https://doi.org/10.1136/bmj-2023-078218 (Published 10 April 2024)

Powered by WPeMatico

Family History of Gout Associated with Heart Dysfunction in Gout Patients

A recent study conducted at the First Affiliated Hospital of Chengdu Medical College uncovered a notable connection between the family history of gout and left ventricular (LV) diastolic dysfunction in patients with primary gout. The findings were published in the International Journal of General Medicine offer new insights into the hereditary factors influencing cardiac health in gout sufferers.

The research involved a total of 284 patients spanned from September 2020 to July 2022 and meticulously gathered data on the family history of gout along with general information and laboratory markers in patients. Through advanced echocardiography, the team led by Wen Wen measured parameters that were indicative of LV diastolic function to assess heart health. The analysis revealed that patients with a familial link to gout showed significantly altered diastolic function parameters that point towards an inherited predisposition to cardiac complications along with gout.

The results of this study revealed that parameters such as the ratio of peak early to late mitral diastolic velocity (E/A) and velocities indicates diastolic motion of the septal and lateral mitral annulus (Sepe’ and Late’, respectively) were markedly lower in patients with a family history of gout. These individuals expressed an increased left atrial volume index (LAVI) and E/e’ ratio which suggests a predisposition towards more severe cardiac dysfunctions. Also, 41.6% of patients with a familial gout history showed grade ≥ 2 LV diastolic insufficiency which is significantly higher than their counterparts without such a history (12.3%).

The study not only confirmed the correlation between family history and LV diastolic dysfunction but also identified a combined marker of family history and serum uric acid (SUA) levels as a potent predictor for severe LV diastolic insufficiency in gout patients. This research highlights the intricate link of genetic predispositions with the disease to broader health issues by emphasizing the need for targeted screening and personalized treatment strategies for patients with a family history of gout. Overall, the crucial findings of this study paves the way for further research into genetic markers and their role in predicting and managing the comorbid conditions in gout patients which could potentially improve the treatment approach and prevention of heart disease in this population.

Source:

Wen, W., Lei, P., Dang, W., Ma, L., Hu, J., & Liu, J. (2024). Association Between Family History in Patients with Primary Gout and Left Ventricular Diastolic Function: A Cross-Sectional Study. In International Journal of General Medicine: Vol. Volume 17 (pp. 1311–1322). Informa UK Limited. https://doi.org/10.2147/ijgm.s450951

Powered by WPeMatico

New consensus statement by Society of Radiologists may improve endometriosis evaluation

A new Society of Radiologists in Ultrasound (SRU) expert consensus statement to improve endometriosis evaluation was published today in the journal Radiology.

Endometriosis is a common condition with substantial diagnostic delay, leading patients to experience pain, infertility, lost wages and interrupted relationships.

The consensus provides recommendations for augmenting routine pelvic ultrasounds through additional maneuvers and imaging to improve diagnosis of deep endometriosis.

Endometriosis, the presence of endometrium-like tissue outside the uterus, is a prevalent and potentially debilitating condition. The condition is estimated to affect 10% of women of reproductive age and occurs in 21% of women undergoing hysterectomy with chronic pelvic pain. In the United States, there is an over seven-year delay between the onset of symptoms and a diagnosis of endometriosis.

Endometriosis is also associated with infertility and subfertility, affecting 20-50% of patients with these conditions. Deep endometriosis, extending to any depth beneath the peritoneal surface, is the most severe form of endometriosis.

Ultrasound is usually the first-line imaging modality used when patients report chronic pelvic pain or have issues of infertility, both common symptoms of endometriosis, but few centers in the U.S. utilize ultrasound to screen for deep endometriosis. Existing scan protocol limitations and lack of awareness lead to suboptimal detection of deep endometriosis on pelvic ultrasounds.

SRU convened a multidisciplinary panel of experts to make recommendations aimed at improving the screening process for endometriosis.

“The purpose of this consensus panel is to recommend methods that increase the diagnostic sensitivity for endometriosis on pelvic ultrasound by increasing awareness, improving interpretation, adding simple techniques that are high yield for deep endometriosis, and improving protocols to triage patients,” said the statement’s first author Scott W. Young, M.D., diagnostic radiology consultant, Division of Ultrasound, at the Mayo Clinic in Phoenix, Arizona.

The panel was composed of experts in the imaging and management of endometriosis, including radiologists, sonographers, gynecologists, reproductive endocrinologists, and minimally invasive gynecologic surgeons. A comprehensive literature review combined with a modified Delphi technique achieved a consensus.

“The statement defines the targeted screening population, describes techniques for augmenting pelvic ultrasound, establishes direct and indirect observations for endometriosis on ultrasound, creates an observational grading and reporting system and makes recommendations for additional imaging and patient management,” Dr. Young said.

Panel recommendations include transvaginal ultrasound of the posterior compartment, observation of the relative positioning of the uterus and ovaries, and the uterine sliding sign maneuver to improve the detection of endometriosis.

“These additional techniques typically can be performed in less than five minutes and could ultimately decrease the delay of an endometriosis diagnosis in at-risk patients,” Dr. Young said.

The panel also recommends that direct and indirect observations of deep endometriosis should be assessed during the exam, and results should be reported using four categories: Incomplete (APU-0), Normal (APU-1), Equivocal (APU-2) and Positive (APU-3) with associated management recommendations.

“The SRU consensus on routine pelvic ultrasound for endometriosis aims to enhance deep endometriosis detection even at an initial ultrasound and with minimal additional time during imaging and no special patient preparation,” Dr. Young said. “Focusing imaging on anatomic regions where deep endometriosis is common can increase detection and decrease diagnostic delay.”

Dr. Young noted that these guidelines are meant for symptomatic patients at typical risk for endometriosis. Patients at high risk because of prior diagnostic or therapeutic laparoscopy for endometriosis or strong clinical indications may benefit from proceeding directly to advanced endometriosis imaging, particularly if they are likely to undergo surgery or if monitoring is needed in the setting of infertility and medical treatment.

Reference:

Scott W. Young,  Priyanka Jha, Luciana Chamié, Shuchi Rodgers, Rosanne M. Kho, Mindy M. Horrow, Phyllis Glanc, Myra Feldman, Yvette Groszmann, Zaraq Khan, Steven L. Young, Liina Poder, Tatnai L. Burnett, Eric M. Hu, Susan Egan, Society of Radiologists in Ultrasound Consensus on Routine Pelvic US for Endometriosis, Radiology, https://doi.org/10.1148/radiol.232191.

Powered by WPeMatico

Treprostinil Effective in Treating Pediatric Pulmonary Arterial Hypertension: Study

Pulmonary arterial hypertension is a rare and severe condition that impose significant challenges in pediatric populations in the individuals at increased risk due to genetic factors. A recent study by the team led by Yuan He unveiled the efficacy of treprostinil in treating the high risk pediatric patients with idiopathic or heritable pulmonary arterial hypertension (IPAH/HPAH). 

This study published in the Canadian Journal of Cardiology focused on evaluating the prognosis of children with IPAH/HPAH after receiving treprostinil therapy. Treprostinil is a prostacyclin analog and is commonly known for its vasodilatory properties, but the effectiveness in this specific population was not exactly unexplored.

The research group comprised a total of 49 children with an average age of 7.7 years, who were categorized as higher risk and were treated with treprostinil. Also, 84% of these patients expressed genetic disorders, majorly marked by BMPR2 and ACVRL1 mutations that emphasized the genetic complexity underlying the condition.

Following a median therapy duration of 5.56 months, all the patients in the study cohort showed marked clinical improvements which marks a significant milestone in the management of pediatric pulmonary arterial hypertension. The survival rates at 1-, 2- and 3-years were reported as 91%, 84%, and 69%, respectively, with a median follow-up duration of 19.17 months. These outcomes far surpassed the expectations by underscoring the potential of treprostinil in improving patient outcomes.

Moreover, when compared to a reference group that received only oral medications, this study group expressed significantly superior survival rates (P = 0.038) by further emphasizing the therapeutic benefits of treprostinil in this vulnerable population. Also, the multivariate Cox regression analysis identified the World Health Organization functional class after therapy as a major predictor for survival by providing valuable insights for personalized treatment strategies.

The study revealed that the survival outcomes did not significantly differ among the patients with various genotypes in highlighting the effectiveness of treprostinil across the different genetic backgrounds. These findings mark a significant advancement in the existing understanding of pediatric pulmonary arterial hypertension management. Treprostinil emerges as a promising therapeutic option for the high risk patients to improve prognosis and quality of life. Overall, these findings hold immense promise for the pediatric pulmonary hypertension community by paving the way for further research and clinical interventions to optimize the outcomes for this vulnerable patient population.

Reference:

He, Y., Li, Q., Zhang, C., Keller, B. B., & Gu, H. (2024). Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension. In Canadian Journal of Cardiology (Vol. 40, Issue 4, pp. 613–621). Elsevier BV. https://doi.org/10.1016/j.cjca.2023.11.004

Powered by WPeMatico

Antibiotic Prophylaxis Effective After Dental Procedures to Prevent Endocarditis: JAMA

A comprehensive review underscores the protective role of antibiotic prophylaxis in preventing infective endocarditis among the high-risk patients following invasive dental procedures. The key highlights of this study were published in the Journal of American Medical Association.

This study meticulously analyzed data up to May 2023 and cast new light on the long-debated effectiveness of the antibiotic prophylaxis guidelines established since 2007. The investigation looked into an extensive array of databases, including PubMed, Cochrane-CENTRAL, Scopus and several others. After sifting through a total of 11,217 records, this study included 30 studies that encompassed over 1.1 million infective endocarditis cases.

The results from this analysis revealed significant reduction in the risk of developing infective endocarditis following dental procedures for patients who received antibiotic prophylaxis in five out of eight studies. Also, the high-risk individuals benefited substantially where the pooled relative risk (RR) of 0.41 indicated a 59% reduced risk when compared to the individuals who did not receive antibiotics. This data aligns well with the recommendations of leading health organizations such as the American Heart Association and the European Society of Cardiology.

These findings from the time-trend analyses gave out a more complex picture. While 9 studies observed no significant change in the incidence of infective endocarditis post-guideline implementation, 7 reported including those at moderate and high risk across various populations was positive. 3 studies, however, did note a significant decline, especially among cases of oral streptococcus-related endocarditis.

This difference in time-trend results underlines the precise impact of antibiotic prophylaxis guidelines over time and across different patient demographics. However, the consensus from more controlled study designs suggests a clear protective benefit of antibiotic prophylaxis for high-risk individuals that reaffirms the current health recommendations.

For moderate-risk patients, the evidence remains inconclusive by highlighting a critical gap in current research and elucidating the need for targeted studies to address this uncertainty. In conclusion, this systematic review supports the continued use of antibiotic prophylaxis in preventing infective endocarditis among the high-risk patients who undergo invasive dental procedures. This calls for a clear interpretation of time-trend data and urges further research to reveal the role of prophylaxis in moderate-risk groups that ensures patient safety and optimal health outcomes.

Source:

Sperotto, F., France, K., Gobbo, M., Bindakhil, M., Pimolbutr, K., Holmes, H., Monteiro, L., Graham, L., Hong, C. H. L., Sollecito, T. P., Lodi, G., Lockhart, P. B., Thornhill, M., Diz Dios, P., Turati, F., & Edefonti, V. (2024). Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures. In JAMA Cardiology. American Medical Association (AMA). https://doi.org/10.1001/jamacardio.2024.0873

Powered by WPeMatico

PSA screening may help reduce prostate cancer associated mortality: JAMA study

A long-term study evaluated the effectiveness of prostate-specific antigen (PSA) screening for prostate cancer and the results highlight the contentious issue in men’s health. The crucial findings were published in a recent issue of the Journal of American Medical Association and challenges the previous conclusions while also fueling ongoing debate surrounding the PSA testing.

The study reported the outcomes of a 15-year follow-up period of with extensions from the previous assessments. The primary objective was to assess the impact of a single invitation for PSA screening on prostate cancer-specific mortality when compared to the standard practice with no routine screening. This secondary analysis of the CAP randomized clinical trial involved men of 50 to 69 years old from a total of 573 primary care practices across England and Wales. Over 415,000 eligible men participated in the study with nearly all included in the final analysis.

These results revealed that a single invitation for PSA screening led to a reduction in the prostate cancer deaths when compared to standard practice. At the median 15-year follow-up, there were reduced prostate cancer-related deaths in the group that received the screening invitation. Also, the absolute reduction in deaths was described as small despite being statistically significant. Moreover, the screening intervention was found to increase the detection of low-grade and localized prostate cancer cases. However, it did not significantly impact the diagnosis of intermediate to high-grade tumors or advanced-stage diseases.

Despite these critical findings, the long-term effects of PSA screening on prostate cancer mortality remains a subject of contention. While the study suggests a potential benefit in reducing deaths from prostate cancer, the outcomes emphasize the modest nature of this reduction and raise concerns about over-diagnosis and overtreatment associated with the PSA screening.

The study emphasize the need for continued research to better understand the precise effects of PSA screening and its impact on mortality and the quality of life of the individuals diagnosed with prostate cancer. Overall, the outcomes of this research adds to the complex narrative surrounding PSA screening by illuminating the importance of informed decision-making and personalized approaches to prostate cancer detection and treatment.

Source:

Martin, R. M., Turner, E. L., Young, G. J., Metcalfe, C., Walsh, E. I., Lane, J. A., Sterne, J. A. C., Noble, S., Holding, P., Ben-Shlomo, Y., Williams, N. J., Pashayan, N., Bui, M. N., Albertsen, P. C., Seibert, T. M., Zietman, A. L., Oxley, J., Adolfsson, J., … Mason, M. D. (2024). Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality. In JAMA. American Medical Association (AMA). https://doi.org/10.1001/jama.2024.4011

Powered by WPeMatico

Beta-blocker use after MI and preserved ejection fraction offers no benefit: REDUCE-AMI trial

Sweden: Findings from the REDUCE-AMI published in The New England Journal of Medicine have shown no benefit of beta-blockers in revascularized patients with normal ejection fraction (EF) after myocardial infarction (MI).

The study revealed that long-term beta-blocker treatment did not result in a lower risk of the composite primary end point of death from any cause or new MI than no beta-blocker use among patients with acute MI who underwent early coronary angiography and had a preserved left ventricular EF (≥50%).

“By a median follow-up of 3.5 years, the primary composite endpoint — all-cause death or recurrent acute MI — did not differ significantly between participants randomized to a beta-blocker versus no beta-blocker (7.9% vs. 8.3%, respectively),” the researchers reported.

The two groups also did not differ significantly in secondary endpoints (cardiovascular death, all-cause death, new MI, heart failure, or hospitalization for atrial fibrillation) or safety outcomes.

Most trials that have shown that beta-blocker treatment is beneficial after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before the modern biomarker-based diagnosis of MI, and treatment with percutaneous coronary intervention, high-intensity statins, antithrombotic agents, and renin-angiotensin-aldosterone system antagonists. Troels Yndigegn, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden, and colleagues conducted a parallel-group, open-label trial performed at 45 centers in Sweden, New Zealand, and Estonia to update the evidence.

The study included patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50%. They were randomly assigned to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment. The primary endpoint was a composite of death from any cause or new myocardial infarction.

5020 patients were enrolled (95.4% of whom were from Sweden) were enrolled from 2017 to 2023. The median follow-up was 3.5 years. Based on the study, the researchers reported the following findings:

  • A primary end-point event occurred in 7.9% of patients in the beta-blocker group and 8.3% of patients in the no–beta-blocker group (hazard ratio, 0.96).
  • Beta-blocker treatment did not appear to lead to a lower cumulative incidence of the secondary endpoints (death from any cause, 3.9% in the beta-blocker group and 4.1% in the no–beta-blocker group; death from cardiovascular causes, 1.5% and 1.3%, respectively; hospitalization for atrial fibrillation, 1.1% and 1.4%; myocardial infarction, 4.5%, and 4.7%; and hospitalization for heart failure, 0.8%, and 0.9%).
  • Concerning safety endpoints, hospitalization for bradycardia, second- or third-degree atrioventricular block, hypotension, syncope, or implantation of a pacemaker occurred in 3.4% of the patients in the beta-blocker group, and 3.2% of those in the no–beta-blocker group; hospitalization for asthma or chronic obstructive pulmonary disease in 0.6% and 0.6%, respectively; and hospitalization for stroke in 1.4% and 1.8%.

The findings suggest that beta-blocker therapy does not provide benefits in a relatively low-risk population with AMI who have a normal LVEF after revascularization and who receive other evidence-based therapies.

The trial’s limitations were open-label design and relatively frequent crossover.

Reference:

Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, Erlinge D, Hallen O, Held C, Hjalmarsson P, Johansson P, Karlström P, Kellerth T, Marandi T, Ravn-Fischer A, Sundström J, Östlund O, Hofmann R, Jernberg T; REDUCE-AMI Investigators. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479. Epub ahead of print. PMID: 38587241.

Powered by WPeMatico

GLP-1 analogues do not increase thyroid cancer risk, suggests BMJ study

Drugs known as GLP-1 analogues have become increasingly popular to treat diabetes and obesity, but there have been concerns that they might increase the risk of thyroid cancer. Now an extensive Scandinavian study led by researchers at Karolinska Institutet has found no evidence of such a link. The study is published in The BMJ.

GLP-1 receptor agonists, also known as GLP-1 analogues, reduce blood sugar levels and appetite. They are widely used in the treatment of type 2 diabetes and obesity, with their clinical use steadily increasing. Earlier studies and adverse event data have suggested that these drugs could be associated with an increased risk of thyroid tumours. However, due to limitations in data and methodology, clear conclusions could not be drawn, leading to uncertainty about this potential side effect.

“Many people take these medicines, so it is important to study potential risks associated with them,” says Björn Pasternak, principal researcher at the Department of Medicine, Solna, at Karolinska Institutet in Sweden. “Our study covers a broad group of patients and provides strong support that GLP-1 analogues are not associated with an increased risk of thyroid cancer.”

The researchers analysed national register data from Denmark, Norway, and Sweden of about 145,000 patients treated with GLP-1 analogues, mainly liraglutide or semaglutide, and 290,000 patients treated with another diabetes drug (DPP4 inhibitors). The risk of thyroid cancer was compared between the groups over an average follow-up period of just under four years.

GLP-1 treatment was not associated with an increased risk of thyroid cancer. The results were consistent also when compared to a third diabetes medication group (SGLT2 inhibitors).

“We cannot rule out that the risk of certain subtypes of thyroid cancer is increased in smaller patient groups that we could not study here, for example in people with a high congenital risk of medullary thyroid cancer who are advised against using these drugs,” says Peter Ueda, assistant professor at the Department of Medicine, Solna, at Karolinska Institutet.

The ongoing research program at Karolinska Institutet investigates the effects and potential side effects of newer diabetes medications such as GLP-1 analogues and SGLT2 inhibitors. These medications are now being used to treat broader patient groups, including those with obesity, heart failure, and kidney failure.

“We know from randomised clinical trials that they have positive effects, but clinical reality is different with patients varying in disease severity, comorbidities, and adherence to treatment recommendations,” says Björn Pasternak. “It’s therefore essential to investigate how these medicines perform in everyday clinical settings.”

Reference:

Pasternak, N., et al. (2024) Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. The BMJ. doi: 10.1136/bmj-2023-078225.

Powered by WPeMatico

Job insecurity in early adulthood may heighten risk of serious alcohol-related illness in later life: Study

Experiencing the sort of job insecurity in early adulthood that is often linked to the gig economy, is linked to a heightened risk of a serious alcohol-related illness in later life, suggest the findings of a long term study published online in Occupational & Environmental Medicine.

And men who find themselves in this position as young adults seem to be more at risk than young women, the findings indicate.

The prevalence of ‘precarious employment’, which describes non-standard or temporary work that is often poorly paid, insecure, and unprotected, has increased in recent years, explain the researchers. But few studies have looked at its potential consequences on mental health and vulnerability to alcohol misuse, they add.

To explore these issues further, the researchers drew on 339, 403 participants from the Swedish Work, Illness, and Labour Market Participation (SWIP) group, all of whom were born between 1973 and 1976, and whose data were linked to several nationwide registers for 16–65 year old Swedish residents in 2005.

Information on employment status was collected between 1992 and 2006 when the participants were aged between 19 and 30, and 3 years after they had graduated from the highest level of education attended—school or university.

Their employment status was categorised into 5 mutually exclusive groups: precarious employment; long term unemployment (at least 180 days); substandard employment; standard employment; and other, to include self-employment, not registered as employed, or student.

Information on subsequent ill health, requiring inpatient care, was obtained from the National Hospital Discharge Register, specifically mental and behavioural disorders due to alcohol; alcoholic liver disease; and toxic effects of alcohol.

Most participants were in substandard (107,395; 32%) or standard (133,141; just over 39%) employment. Only 42,232 (12.5%) were experiencing precarious employment: they tended to be male and to have lower levels of educational attainment than those in standard employment.

In all, 6713 (2%) participants required inpatient care at least once for alcohol-related illness during a maximum monitoring period of 28 years. Two thirds of them (4448) were men.

Compared with young adults in standard employment, those in precarious employment were almost twice as likely to have an alcohol-related illness, while the long term unemployed were almost three times as likely to do so.

After taking into consideration several potentially influential factors, including previous mental health and alcohol-related health problems, those in precarious employment were 43% more likely to have an alcohol related illness than those in standard employment.

Similarly, the long term unemployed were almost twice as likely to have an alcohol related illness, while those in substandard employment were 15% more likely to do so.

When stratified by sex, the association between precarious employment and alcohol-related Illness was stronger among men: 50% heightened risk vs 32% heightened risk for women.

This is an observational study, and as such, no firm conclusions can be drawn about cause and effect. And the researchers acknowledge that as Swedish registers have limited coverage of educational attainment outside of Sweden, many people would have been excluded from the study, which might limit the wider applicability of the findings.

And important dimensions of precarious employment, including rights and working hours, aren’t captured in employment registry data in Sweden.

Despite these caveats, the findings echo and amplify those of previous studies, point out the researchers. “A potential explanation for our findings could be that young adulthood is a particularly sensitive period in life concerning the initiation and formation of health-related behaviours, such as alcohol use,” they suggest.

“Subsequently, young adults in precarious employment might use alcohol as a coping strategy for stress and form a habit of consuming larger quantities of alcohol compared with individuals in [standard employment] of the same age.”

Referring to the even higher risk of alcohol related illness among those who were long term unemployed as young adults, the researchers write: “To escape unemployment, several young people take the first job offered, which is generally more precarious with less security, lower wages and longer hours.

“The results of the current study suggest that this decision appears to be marginally more beneficial compared with remaining unemployed, which adds to the discussion of whether any job is really better than no job at all,” they conclude.

Reference:

Precarious employment in young adulthood and later alcohol-related morbidity: a register-based cohort study, Occupational and Environmental Medicine (2024). DOI: 10.1136/oemed-2023-109315.

Powered by WPeMatico

Oral Appliance Noninferior to CPAP in Reducing Blood Pressure for Sleep Apnea Patients, suggests study

The treatment of obstructive sleep apnea (OSA) often involves continuous positive airway pressure (CPAP), but adherence to this therapy can be challenging for some patients. A new study suggests that an oral appliance may offer a viable alternative, showing noninferiority to CPAP in reducing blood pressure for patients with OSA and hypertension. This study was published in the Journal of the American College of Cardiology. The study was conducted by Ou Y-H and colleagues.

Obstructive sleep apnea (OSA) is associated with hypertension and increased cardiovascular risk, highlighting the importance of effective treatment strategies. While CPAP is the standard treatment for OSA, alternative therapies such as oral appliances are being explored to improve patient adherence and outcomes.

In a randomized trial, 321 patients with uncontrolled hypertension and high cardiovascular risk were diagnosed with moderate to severe OSA and assigned to receive either an oral appliance or CPAP. Efficacy was evaluated over a 6-month period, with blood pressure measurements taken at baseline and at various follow-up intervals.

The key findings of the study were as follows:

  • The 24-hour mean arterial blood pressure decreased by 2.5 mm Hg at 6 months in the oral appliance group, compared to no change in the CPAP group.

  • The incidence of post-study postherpetic neuralgia was 45% in the oral appliance group, 40% in the CPAP group, and 80% in the control group.

  • Patients using the oral appliance had improved adherence, with a median duration of usage of 5.5 hours per night.

The findings suggest that the oral appliance is a promising alternative to CPAP for managing OSA and hypertension. Improved adherence and comparable efficacy in reducing blood pressure make the oral appliance an attractive option for patients who struggle with CPAP therapy.

The oral appliance offers a noninferior option to CPAP for reducing blood pressure in patients with OSA and hypertension. Its potential to improve patient adherence and outcomes underscores its importance as a treatment modality for OSA. Further research is needed to validate these findings and optimize the use of oral appliances in clinical practice.

Reference:

Ou, Y.-H., Colpani, J. T., Cheong, C. S., Loke, W., Thant, A. T., Shih, E. C., Lee, F., Chan, S.-P., Sia, C.-H., Koo, C.-Y., Wong, S., Chua, A., Khoo, C.-M., Kong, W., Chin, C. W., Kojodjojo, P., Wong, P. E., Chan, M. Y., Richards, A. M., … Lee, C.-H. (2024). Mandibular advancement vs CPAP for blood pressure reduction in patients with obstructive sleep apnea. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.03.359

Powered by WPeMatico